The Third Eye That Went Dark: How an Ancient Light Sensor Became the Body’s Clock, Mood Regulator, and Inner Psychedelic

‍ ‍

Deep inside your brain, tucked between the two hemispheres, sits a pea-sized gland that once looked out at the sky. The pineal gland is a living relic of a time when vertebrates literally had a third eye on top of their heads — and its slow evolutionary journey from a light-sensing organ to a hormone-releasing one is one of the strangest stories in biology.

‍ ‍

From “third eye” to endocrine organ

‍ ‍

In early vertebrates, a photoreceptive organ sat on the roof of the primitive brain and sensed light directly. In fish, amphibians, and reptiles, its descendants still do: their pineal complex contains real photoreceptor cells, and in some lizards the parietal eye on top of the skull even has a rudimentary lens — a “semi-visual” light detector used partly for thermoregulation [1, 2]. In lower vertebrates this intracranial structure responds to light on the head by changing its neural activity; in birds and mammals, the same gland has lost its photoreceptors, and light now reaches it only indirectly, through the lateral eyes [3].

‍ ‍

The pineal and the retina, it turns out, are evolutionary siblings — different descendants of the same ancestral photoreceptor [4, 5]. Over hundreds of millions of years, one side of that ancient tissue became our eyes. The other became a gland.

‍ ‍

How light still reaches the mammalian pineal

‍ ‍

In humans the pineal is blind, but it is not disconnected from light. Photons hitting the retina activate a special class of cells that express melanopsin, a pigment tuned to blue light [6]. The signal travels along the to a part of the brain called the suprachiasmatic nucleus (SCN) of the hypothalamus — the brain’s master clock [7, 8]. From the SCN, the signal takes a long detour down the spinal cord and back up to the pineal along sympathetic nerves [9]. Cut those sympathetic fibers and light loses its grip on the gland entirely [10].

‍ ‍

At night, when that pathway falls silent, the pineal releases melatonin. During the day, light shuts it back down. In effect, the pineal translates the ancient question “is it light out?” into a chemical answer that every organ in your body can read.

‍ ‍

The true master gland

‍ ‍

The pituitary tends to get all the credit as “the master gland,” but the pineal is the master’s master’s clock. Its melatonin signal tells the pituitary and gonads what season it is, gates reproductive timing, sets the sleep-wake cycle, tunes body temperature and immune rhythms, and coordinates dozens of tissues into a common day. In seasonal mammals, prolonged darkness makes the pineal strongly anti-gonadotropic — it shrinks the reproductive organs, in direct opposition to the pituitary’s gonad-stimulating hormones [11]. Pineal and pituitary work like a photoperiodic push-pull: light-driven pituitary drive turns reproduction on, dark-driven pineal signaling turns it down.

‍ ‍

Melatonin also shifts the balance of the autonomic nervous system. Its synthesis is driven by nighttime sympathetic (“fight or flight”) outflow from the superior cervical ganglion [9, 10], yet once released, the hormone induces sleep and biases physiology toward the opposite parasympathetic (“rest and digest”) state — slower heart rate, lower blood pressure, restorative sleep, quieter digestion [8]. In a sense, the pineal is the switch that lets the sympathetic system hand the body over to the parasympathetic one each night.

‍ ‍

When the inner clock drifts: light, mood, and mental health

‍ ‍

If the pineal is a nightly signal that tells the body “it is dark, rest now,” then anything that garbles that signal — a clock that runs late, a system that overreacts to a lamp — can ripple outward into mood and behavior. Two conditions show this especially clearly.

‍ ‍

Obsessive-compulsive disorder: a clock that runs late. People with OCD tend to fall asleep late, stay up into the small hours, and struggle to wake in the morning. When researchers measure the nightly rise of melatonin directly, they find it happens hours later than it should [12]. Brain scans have also found that the pineal gland itself is, on average, smaller in people with OCD than in healthy volunteers [13]. And when the standard serotonin-boosting medications fail, some patients improve when doctors add agomelatine, a drug that acts directly on melatonin receptors and helps reset the inner clock [14]. The picture is of a timing system running out of step with the day.

‍ ‍

Bipolar disorder: a clock that overreacts to light. In bipolar disorder the problem looks almost opposite. The melatonin system is unusually sensitive to light. A classic experiment in the 1980s showed that when bipolar patients (even when well and off medication) were exposed to light at night, their melatonin levels fell about twice as much as in healthy controls [15]. Follow-up work found the same over-reactivity in the young, still-healthy children of bipolar parents, hinting that light sensitivity may be one of the earliest fingerprints of the disorder [16]. More recent studies with blue light — the wavelength the inner clock is most tuned to — confirm that evening exposure throws the bipolar clock off far more than a healthy one [17]. This has led to the striking idea that darkness can be a treatment: patients who wear amber “blue-blocker” glasses in the evening, or dim their screens, preserve their nighttime melatonin and often sleep better, with about half reporting real benefit [18]. Melatonin taken as a supplement has also been tested as an add-on during manic episodes, with mixed but sometimes encouraging results [19, 20].

‍ ‍

An unexpected twist: the pineal and psychedelics

‍ ‍

Here the story takes a strange turn. When chemists began looking closely at what the pineal actually contains, they found more than just melatonin. They found molecules that look uncannily like the active ingredients of one of the world’s most famous psychedelic brews — ayahuasca.

‍ ‍

Ayahuasca is an Amazonian tea made from two plants. One contributes N,N-dimethyltryptamine (DMT), a powerful, short-acting psychedelic; the other contributes β-carbolines like harmine and harmaline, which are natural monoamine oxidase inhibitors that keep the DMT from being destroyed in the gut and make the brew orally active [21]. Together they produce the ayahuasca experience.

‍ ‍

The pineal gland, it turns out, makes chemical cousins of both.

‍ ‍

•            In the 1980s, researchers isolated pinoline — chemical name 6-methoxy-tetrahydro-β-carboline — from the pineal gland of birds. It is structurally almost identical to the harmine and harmaline of ayahuasca [22].

•            In 2013, using tiny probes to sample fluid directly from the rat pineal, scientists reported the first direct detection of DMT in pineal tissue [23].

•            A 2019 study went further, showing that the enzymes needed to make DMT are expressed in the pineal, cerebral cortex, and choroid plexus of both rats and humans — and that living rat brains release DMT at concentrations comparable to classical neurotransmitters like serotonin [24].

‍ ‍

It’s important to be careful here: popular claims that the pineal is a “DMT factory” driving dreams or near-death experiences are still speculative, and the amounts released in ordinary life appear to be small [25, 26]. But the chemistry is real, and it is there.

The clinical promise. Whatever the natural role of endogenous DMT turns out to be, its cousins are already reshaping psychiatry. In a placebo-controlled trial in patients with treatment-resistant depression, a single dose of ayahuasca produced rapid antidepressant effects that were still present a week later, with response rates roughly twice those of placebo [27]. More recent trials have tested vaporized DMT on its own — sidestepping the long, difficult ayahuasca session in favor of a 10–20-minute experience — with early signs of rapid, sustained antidepressant effects in patients who had failed other treatments [28]. The field is moving fast, and pineal-adjacent chemistry is at the center of it.

‍ ‍

The takeaway

‍ ‍

The pineal began as a literal eye and ended up as a chemical clock. It no longer sees light, but it still listens for it — through a long retinal detour that ends in a nightly puff of melatonin. That signal tells the pituitary when to breed, the autonomic system when to rest, and the brain when it is safe to sleep. When the signal drifts late, we get rigidity; when it swings wildly with the light, we get instability. An ancient third eye, blinded but not silenced, still runs the show.

‍ ‍

‍ ‍

References

‍ ‍

1.          Vigh, B., Manzano, M. J., Zádori, A., Frank, C. L., Lukáts, Á., Röhlich, P., Szél, Á., & Dávid, C. (2002). Nonvisual photoreceptors of the deep brain, pineal organs and retina. https://www.semanticscholar.org/paper/f368ecd304455d447c132db89bf71f7a8c02200c

‍ ‍

2.          Dodt, E. (1973). The parietal eye (pineal and parietal organs) of lower vertebrates. https://www.semanticscholar.org/paper/cf1ce8f05a1a2270e5b41c351c79d4f8dac82b87

‍ ‍

3.          Hamasaki, D., & Eder, D. (1977). Adaptive radiation of the pineal system. https://www.semanticscholar.org/paper/9ff2effca1a062e1875fc8c60b5f03e426410e7b

‍ ‍

4.          Kafetzis, G., Bok, M., Baden, T., & Nilsson, D.-E. (2026). Evolution of the vertebrate retina by repurposing of a composite ancestral median eye. Current Biology. https://www.cell.com/current-biology/pdf/S0960-9822(25)01676-8.pdf

‍ ‍

5.          Mano, H., & Fukada, Y. (2007). A median third eye: Pineal gland retraces evolution of vertebrate photoreceptive organs. https://onlinelibrary.wiley.com/doi/pdfdirect/10.1562/2006-02-24-IR-813

‍ ‍

6.          Gooley, J., Lu, J., Chou, T., Scammell, T., & Saper, C. (2001). Melanopsin in cells of origin of the retinohypothalamic tract. Nature Neuroscience. https://www.nature.com/articles/nn768.pdf

‍ ‍

7.          Moore, R. (1995). Organization of the mammalian circadian system. https://www.semanticscholar.org/paper/a9eb94d5d53d256296f4e91be39b89848638f7ac

‍ ‍

8.          Ma, M., & Morrison, E. H. (2020). Neuroanatomy, nucleus suprachiasmatic. https://www.semanticscholar.org/paper/2da5cfdbd90750dfa5419a888f66d343e1914317

‍ ‍

9.          Teclemariam-Mesbah, R., ter Horst, G. J., Postema, F., Wortel, J., & Buijs, R. (1999). Anatomical demonstration of the suprachiasmatic nucleus–pineal pathway. Journal of Comparative Neurology, 406, 171–182. https://www.semanticscholar.org/paper/d66feed4538203de84bd5e2f2609776c36333596

‍ ‍

10.     Wurtman, R., Axelrod, J., & Fischer, J. (1964). Melatonin synthesis in the pineal gland: Effect of light mediated by the sympathetic nervous system. https://www.semanticscholar.org/paper/6a572dd1b0c3a72a9d3457ab771bd5736a8e5e85

‍ ‍

11.     Reiter, R., & Sorrentino, S. (1970). Reproductive effects of the mammalian pineal. https://academic.oup.com/icb/article-pdf/10/2/247/6080352/10-2-247.pdf

‍ ‍

12.     Coles, M., Schubert, J., Stewart, E., Sharkey, K., & Deak, M. (2020). Sleep duration and timing in obsessive-compulsive disorder (OCD): Evidence for circadian phase delay. https://www.semanticscholar.org/paper/ee945f72e0b05cbe9878c4918855ef8656433ce0

‍ ‍

13.     Atmaca, M., Yıldız, S., Tabara, M. F., Gurok, M., Yildirim, M., & Yildirim, H. (2024). Reduced pineal gland volume in patients with obsessive-compulsive disorder. https://www.semanticscholar.org/paper/4547e406c67acefd2cd87fdfcac170d31dc104b1

‍ ‍

14.     Tzavellas, E., Karaiskos, D., Ilias, I., Liappas, I., & Paparrigopoulos, T. (2014). Agomelatine augmentation in obsessive compulsive disorder: A preliminary report. https://www.semanticscholar.org/paper/c2c418a7621500d5085a7d304fde3648eedb5e8c

‍ ‍

15.     Lewy, A., Nurnberger, J., Wehr, T., Pack, D., Becker, L. E., Powell, R. L., & Newsome, D. (1985). Supersensitivity to light: Possible trait marker for manic-depressive illness. https://www.semanticscholar.org/paper/855147f232e6588bf01822a0864aad8e5d111f85

‍ ‍

16.     Nurnberger, J., Berrettini, W., Tamarkin, L., Hamovit, J., Norton, J. A., & Gershon, E. (1988). Supersensitivity to melatonin suppression by light in young people at high risk for affective disorder: A preliminary report. https://www.semanticscholar.org/paper/b27c240b40d52354ecc43f0bd4c062d3555f5c2a

‍ ‍

17.     Ritter, P., Soltmann, B., Sauer, C., Yakac, A., Boekstaegers, L., Reichard, M., Koenitz, K., Bauer, M., Güldner, H., Neumann, S., Wieland, F., & Skene, D. (2021). Supersensitivity of patients with bipolar I disorder to light-induced phase delay by narrow bandwidth blue light. Biological Psychiatry Global Open Science. https://doi.org/10.1016/j.bpsgos.2021.06.004

‍ ‍

18.     Phelps, J. (2016). New zero-risk treatment for mania. https://www.semanticscholar.org/paper/2301e8290cb92473078ff969ed110a49e3a6c888

‍ ‍

19.     Mehrpooya, M., Ghasemian, Z., Amini, K., Bakhtiari, K., Zamanirafe, M., Keshavarzi, A., Mohammadi, Y., & Ahmadimoghaddam, D. (2024). Add-on therapy with melatonin in the acute bipolar mania treatment: Results of a randomized, placebo-controlled trial. https://www.semanticscholar.org/paper/ca83a242cfdfe776cc69c41bf8a2094ed37d036d

‍ ‍

20.     Kishi, T., Nishiyama, H., Kimura, Y., Sadaka, T., Terada, A., Tatsumi, Y., Wakahara, M., & Iwata, N. (2021). Melatonin receptor agonists for bipolar mania: A systematic review and meta-analyses of double-blind randomized placebo-controlled trials. https://www.semanticscholar.org/paper/147cc59b3062f2f2ccf63dccebb04f04d62e9f4c

‍ ‍

21.     McKenna, D., Towers, G., & Abbott, F. (1984). Monoamine oxidase inhibitors in South American hallucinogenic plants: Tryptamine and beta-carboline constituents of ayahuasca. https://www.semanticscholar.org/paper/beef2264b8b14dab374191450f645cd26e09518f

‍ ‍

22.     Kari, I. (1981). 6-Methoxy-1,2,3,4-tetrahydro-β-carboline in pineal gland of chicken and cock. FEBS Letters, 127(2), 281–284. https://febs.onlinelibrary.wiley.com/doi/pdfdirect/10.1016/0014-5793%2881%2980223-2

‍ ‍

23.     Barker, S., Borjigin, J., Lomnicka, I., & Strassman, R. (2013). LC/MS/MS analysis of the endogenous dimethyltryptamine hallucinogens, their precursors, and major metabolites in rat pineal gland microdialysate. https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/bmc.2981

‍ ‍

24.     Dean, J. G., Liu, T., Huff, S., Sheler, B., Barker, S., Strassman, R., Wang, M. M., & Borjigin, J. (2019). Biosynthesis and extracellular concentrations of N,N-dimethyltryptamine (DMT) in mammalian brain. Scientific Reports. https://www.nature.com/articles/s41598-019-45812-w.pdf

‍ ‍

25.     Schimmelpfennig, J., & Jankowiak-Siuda, K. (2025). Exploring DMT: Endogenous role and therapeutic potential. https://www.semanticscholar.org/paper/5774d4da85ec99b0b5e97b06b68facaa3929625e

‍ ‍

26.     Barker, S. (2018). N,N-Dimethyltryptamine (DMT), an endogenous hallucinogen: Past, present, and future research to determine its role and function. Frontiers in Neuroscience. https://www.frontiersin.org/articles/10.3389/fnins.2018.00536/pdf

‍ ‍

27.     Palhano-Fontes, F., Barreto, D., Onias, H., Andrade, K., Novaes, M. M., Pessoa, J., Mota-Rolim, S., Osório, F., Sanches, R., dos Santos, R. G., Tófoli, L. F., Silveira, G., Yonamine, M., Riba, J., Santos, F., Silva-Junior, A. A., Alchieri, J., Galvão-Coelho, N., Lobão-Soares, B., Hallak, J., Arcoverde, E., Maia-de-Oliveira, J. P., & Araujo, D. (2018). Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: A randomized placebo-controlled trial. https://www.cambridge.org/core/services/aop-cambridge-core/content/view/E67A8A4BBE4F5F14DE8552DB9A0CBC97/S0033291718001356a.pdf/div-class-title-rapid-antidepressant-effects-of-the-psychedelic-ayahuasca-in-treatment-resistant-depression-a-randomized-placebo-controlled-trial-div.pdf

‍ ‍

28.     Falchi-Carvalho, M., Palhano-Fontes, F., Wießner, I., Barros, H., Bolcont, R., Laborde, S., Silva, S. R. B., Montanini, D., Barbosa, D. C., Teixeira, E., Florence-Vilela, R., Almeida, R., de Macedo, R. K. A., Arichelle, F., Pantrigo, É. J., Costa-Macedo, J. V., Nunes, J. A. C., Costa Neto, L. A. A., Ferreira, L. F. N., Corrêa, L. D., Bezerra, R. B. C., Arcoverde, E., Galvão-Coelho, N., & Araujo, D. B. (2025). Rapid and sustained antidepressant effects of vaporized N,N-dimethyltryptamine: A phase 2a clinical trial in treatment-resistant depression. https://www.semanticscholar.org/paper/539a9f82e419080f7a4adb5b2e08a0af925b0d9a

‍ ‍

‍ ‍

Previous
Previous

Quantitative EEG in Depression: Predictors of Treatment Response

Next
Next

Personalizing TMS with qEEG guidance: Two Ways to Stop Guessing Where to Stimulate